Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom's flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom's innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market.
Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.
FTHM and FBLG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Fathom Holdings Inc.
Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
'Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]
--END--
SOURCE: RedChip Companies, Inc. (Media Suite)
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Citi Maintains Neutral Rating on Simon Property Group (SPG)
Simon Property Group, Inc. (NYSE:SPG) is one of the most undervalued stocks. On June 17, Citi trimmed its price target on SPG from $185 to $170 while reiterating a Neutral rating on the stock. The company adjusted its 2025 funds from operations (FFO) estimate downward to $12.21 from the previous $12.52, adding the impact of Q1 results that included one-time expenses and investment losses of $0.28 per share. Similarly, Citi revised its 2025 core FFO forecast to $12.49, a slight decrease from $12.52, mainly driven by more conservative projections for net operating income. A rooftop view of a bustling downtown area, emphasizing the company's investments in the real estate sector. The updated price target implies a valuation multiple of approximately 14x the expected 2025 core FFO, down from the earlier multiple of around 15x. Citi attributed this multiple compression to increased uncertainty regarding potential tariff impacts and the overall creditworthiness of tenants. This adjustment in price target stems from Simon's recent earnings performance and denotes a conservative outlook on the retail property market amid broader economic headwinds. Simon Property Group, Inc. (NYSE:SPG) is a self-managed and self-administered REIT specializing in the ownership, development, and operation of premier retail and mixed-use properties, including malls, outlets, and international destinations. While we acknowledge the potential of SPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Truist Lifts COPT Defense Properties (CDP) PT to $30
COPT Defense Properties (NYSE:CDP) is one of the most undervalued stocks. On June 10, Truist maintained a Hold rating on CDP and raised the price target from $29 to $30. With a robust 4.31% yield, the company has consistently paid dividends for the past 34 years, indicating its commitment to shareholder returns. The target price update reflects a refined valuation approach that involves discounted cash flow analysis along with forecasted net asset value. Analysts reported that COPT Defense Properties (NYSE:CDP) is advancing three developments set to launch in 2025, with more projects on deck for 2026 and 2027. The $308 million active portfolio is 62% pre-leased, with 30% of the costs already invested. Occupancy at COPT Defense is forecasted to dip slightly to 91.9% by the end of 2025, compared to 92.3% in the first quarter. The firm also projects a low single-digit positive increase in GAAP rental spreads. A security guard patrolling a defense facility, protecting critical technologies. Analysts indicate that COPT Defense Properties (NYSE:CDP) is unlikely to engage in any mergers, acquisitions, or property disposals in 2025. However, they are factoring in a $400 million unsecured note issuance for the fourth quarter. COPT Defense, a self-managed REIT, focuses on the ownership, operation, and development of mission-critical real estate assets located near or within major US Government defense installations. While we acknowledge the potential of CDP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
UnitedHealth Stock Is One of the Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip?
Wall Street is cheering fresh highs as the S&P 500 Index ($SPX) wraps a solid second quarter, closing June 2025 strong. The rally has been powered by cooling inflation, resilient earnings, and fading tariff concerns after April's policy shock. Just three months back, the market briefly dipped toward bear territory amid geopolitical tensions, China's AI push, tariff fears, and fiscal uncertainty, keeping investors on edge about the rebound's staying power. Despite the S&P rallying over 28% from its April lows of $4,835, the bull run has still left many big names behind. Nearly a third of the index's stocks still ended the first half of 2025 in the red. UnitedHealth (UNH), a giant in health insurance and managed care services, has plunged 39% so far in 2025. UNH stock has been hit by soaring Medicare Advantage costs, a probe into Medicare fraud, and a sudden CEO exit, making it the index's fourth-worst performer. Michael Saylor Says 'You'll Wish You'd Bought More' Bitcoin as MicroStrategy Doubles Down Is Microsoft Stock About to Go Nuclear? Is Super Micro Computer Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! While UNH is at five-year lows, a 1.8% five-day bounce hints at some life. With the dividend-paying stock halved and trading at a compelling valuation, is this a classic 'buy the dip' setup? Or a moment for caution despite the allure of value and yield? Founded in 1977, UnitedHealth has grown into a $295 billion healthcare heavyweight. With its deep roots in health insurance and care services, the company runs on two powerhouse engines: UnitedHealthcare and Optum. UnitedHealthcare handles the insurance side, offering plans that serve over 50 million people. It's the backbone, giving the company scale, reach, and reliable revenue. But it's Optum that brings the spark, driving growth through data, tech, and pharmacy solutions. From analytics to care delivery, Optum's strategy pushes innovation across the system. Together, these segments give the company its edge in a complex healthcare landscape. UNH stock has been in free fall in 2025, hitting a low of $248.88 in May. Over the past 52 weeks, the stock has declined 38%, trailing far behind the broader S&P's surge of 13%. However, UNH stock is rebounding, up 1% over the past month. UnitedHealth's downfall in 2025 was not just a single bad headline. It was a chain reaction that started fast and spiraled hard. It kicked off on April 17, when the company shocked the Street by slashing its full-year earnings forecast. This was because a flood of higher-acuity Medicare Advantage patients drove costs far beyond expectations, exposing just how outdated and fragile their forecasting models had become. Then May hit like a wrecking ball. CEO Andrew Witty abruptly resigned, raising eyebrows amid growing pressure. Days later, reports surfaced of a U.S. Department of Justice investigation into alleged Medicare fraud. By mid-May, the stock had crashed, hitting five-year lows. Just when it seemed the damage was done, more scandal dropped with accusations of UnitedHealth secretly paying nursing homes to avoid costly hospital transfers. Even insider buying gave only a brief lift to UNH. In a short span, UnitedHealth went from a rock-solid name to a cautionary tale unraveling in real time. After its brutal springtime plunge, UNH stock is priced at 14 times forward earnings and 0.7 times sales, trading in bargain territory. Those multiples sit well below both the sector medians and its own five-year averages, catching the eye of value hunters sniffing out a possible rebound. Despite the stock's decline, UnitedHealth has signaled some confidence where it counts: dividends. In June, the company hiked its quarterly payout by 5.2% to $2.21, marking 15 consecutive years of increases. Paid out on June 24, the hike pushed its annual yield near 2.6%. On April 17, UnitedHealth reported Q1 2025 earnings, and it wasn't the kind of update Wall Street wanted to hear. Revenue climbed 9.8% year-over-year (YOY) to $109.6 billion but still came in shy of expectations. Adjusted EPS rose 4.2% to $7.20 yet missed the estimated mark of $7.27. UnitedHealthcare, the insurance arm, posted a solid 12.2% revenue gain to $84.6 billion. Meanwhile, Optum saw more modest growth of 4.6% to $63.9 billion, with Optum Rx doing the heavy lifting. Still, rising costs loomed large. Total operating expenses surged 9.4% annually to $100.5 billion. On the brighter side, the company exited the quarter with $34.3 billion in cash and short-term investments and generated $5.5 billion in operating cash flow. Shareholders weren't left in the cold either, with over $5 billion returned through buybacks and dividends. UnitedHealth's steep selloff wasn't just about Q1 results. It was the guidance cut that really rattled sentiment. Management slashed its 2025 adjusted EPS outlook to between $26 and $26.50, down from the initially forecast range of $29.50 to $30 in December 2024 and below fiscal 2024 adjusted EPS of $27.66. Surging Medicare Advantage costs and shifts in Optum's patient mix have taken a real bite. Now, all eyes are on the fiscal Q2 report, expected to be released on July 29 before the market opens. Analysts forecast the Q2 bottom line to be around $5.08 per share, down 25% YOY. Looking to fiscal 2025, adjusted EPS is expected to decline 20% annually to $22.07, then surge by 15% to $25.39 in fiscal 2026. Last Wednesday, UBS reiterated its 'Buy' rating on UNH stock but trimmed the price target to $385 from $400. The cut followed CEO Stephen Hemsley's cautious tone at the June 2 meeting, hinting at more conservative 2025 guidance. UBS anticipates fiscal 2025 EPS closer to $20, down from the earlier $22.50 consensus. Margins were also revised, with Medicare Advantage trimmed to 1.5% and Optum Health lowered to 4.5%. Despite the recent shakeups, Wall Street hasn't completely hit the panic button yet. Last month, UnitedHealth shook things up by axing broker commissions on select Medicare Advantage plans — a move aimed at trimming the cost that forced it to yank full-year guidance. Hightower Chief Investment Strategist Stephanie Link called it a smart pivot, saying the same issue 'got them in trouble' to begin with. Link is bracing for short-term volatility but stays bullish long-term, calling UNH stock 'too cheap' for a top-tier name in the industry. There's still optimism in the air, but with a touch of caution. UNH stock has a 'Moderate Buy' consensus overall, down from a consensus 'Strong Buy' rating a month ago. Of the 24 analysts covering the stock, 15 advise a 'Strong Buy,' two suggest a 'Moderate Buy,' and seven analysts play it safe with a 'Hold.' The mean price target of $363.43 implies shares could rise as much as 18%. The Street-high target of $440, way below this year's highs, signals that UNH has an upside potential of 43% from current levels. The U.S. healthcare industry, despite constant political firestorms, is built to endure. For years, UnitedHealth has stood as its crown jewel. Defensive, dividend-paying, and shock-resistant, it has been the kind of stock long-term investors can count on. But 2025 has shattered that illusion. While the broader market climbs to record highs, UnitedHealth's dramatic plunge reminds us that even giants can stumble hard. Sure, UNH stock now trades at a discount, offering an attractive dividend yield. Insiders are buying shares, and UnitedHealth still commands significant market share and robust cash flow. But is this really a 'buy the dip' moment? It's probably a bet that management can steady the ship, and the storm eventually clears. Until then, UnitedHealth sits in a gray zone between legacy and uncertainty, where long-term promise collides with short-term pain. Investors should exercise caution before jumping in. On the date of publication, Sristi Suman Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
